[go: up one dir, main page]

DE60019473D1 - (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien - Google Patents

(S,S)-Reboxetin zur Behandlung von peripheren Neuropathien

Info

Publication number
DE60019473D1
DE60019473D1 DE60019473T DE60019473T DE60019473D1 DE 60019473 D1 DE60019473 D1 DE 60019473D1 DE 60019473 T DE60019473 T DE 60019473T DE 60019473 T DE60019473 T DE 60019473T DE 60019473 D1 DE60019473 D1 DE 60019473D1
Authority
DE
Germany
Prior art keywords
reboxetine
treatment
peripheral neuropathies
neuropathies
peripheral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019473T
Other languages
English (en)
Other versions
DE60019473T2 (de
Inventor
Saeeduddin Ahmed
Lars Birgerson
Pasquale Cetera
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Erik H F Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60019473(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE60019473D1 publication Critical patent/DE60019473D1/de
Application granted granted Critical
Publication of DE60019473T2 publication Critical patent/DE60019473T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60019473T 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien Expired - Lifetime DE60019473T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US141968P 1999-07-01
US14413199P 1999-07-16 1999-07-16
US144131P 1999-07-16
US15825699P 1999-10-06 1999-10-06
US158256P 1999-10-06
US17038199P 1999-12-13 1999-12-13
US170381P 1999-12-13

Publications (2)

Publication Number Publication Date
DE60019473D1 true DE60019473D1 (de) 2005-05-19
DE60019473T2 DE60019473T2 (de) 2006-02-23

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz

Family Applications After (6)

Application Number Title Priority Date Filing Date
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom

Country Status (30)

Country Link
US (18) US6465458B1 (de)
EP (3) EP2087892A3 (de)
JP (3) JP2003503450A (de)
KR (5) KR100948757B1 (de)
CN (5) CN1660110A (de)
AR (1) AR035158A1 (de)
AT (9) ATE304358T1 (de)
AU (2) AU771258B2 (de)
BR (1) BR0012136A (de)
CA (2) CA2375908C (de)
CL (3) CL2008002867A1 (de)
CO (1) CO5190662A1 (de)
CZ (1) CZ299847B6 (de)
DE (9) DE60026704T2 (de)
DK (4) DK1632234T3 (de)
EA (6) EA200801806A1 (de)
ES (9) ES2247572T3 (de)
GE (1) GEP20094798B (de)
HU (1) HUP0201623A3 (de)
IL (3) IL147246A0 (de)
MX (1) MXPA02000562A (de)
MY (1) MY137348A (de)
NO (4) NO20016406L (de)
NZ (2) NZ515885A (de)
PE (1) PE20010684A1 (de)
PL (1) PL196996B1 (de)
PT (5) PT1459751E (de)
SK (5) SK286668B6 (de)
TW (9) TWI245631B (de)
WO (1) WO2001001973A2 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2247572T3 (es) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2405565A1 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
KR20030051812A (ko) * 2000-11-15 2003-06-25 일라이 릴리 앤드 캄파니 불안 장애의 치료
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
DK1397145T3 (da) * 2001-06-19 2007-01-02 Norbert Mueller Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005515199A (ja) * 2001-11-30 2005-05-26 イーライ・リリー・アンド・カンパニー チック障害の治療のためのノルエピネフリン再取込インヒビターの使用
SK2442004A3 (en) * 2001-12-11 2004-12-01 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
EP2301537A1 (de) 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
JP2005531594A (ja) * 2002-05-30 2005-10-20 ニューロサーチ、アクティーゼルスカブ 慢性苦痛の治療用トリプルモノアミン再取り込み阻害剤
CA2489763C (en) * 2002-06-17 2007-12-18 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
AU2003261245A1 (en) 2002-08-23 2004-03-11 Eli Lilly And Company Benzyl morpholine derivatives
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
EP1716126B1 (de) * 2003-12-23 2009-02-25 Eli Lilly And Company Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
CA2564994A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR20070029740A (ko) * 2004-06-09 2007-03-14 화이자 인코포레이티드 통증 치료를 위한 레복세틴의 용도
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
PT1781260E (pt) 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
EP2468271B1 (de) 2007-03-09 2014-07-16 Chelsea Therapeutics, Inc. Pharmazeutische Zusammensetzung enthaltend Droxidopa zur Behandlung von Fibromyalgie
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
BRPI0810773A2 (pt) * 2007-04-30 2014-10-07 Adolor Corp Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
ES2495366T3 (es) * 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
EP2523557B1 (de) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
EP3693020A1 (de) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
JP2023504685A (ja) * 2019-12-03 2023-02-06 アクスサム セラピューティクス インコーポレイテッド 神経系障害を治療するためのレボキセチンを含む組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
CN1146421C (zh) 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
EP0906104A4 (de) 1996-03-25 2003-12-10 Lilly Co Eli Schmerzbehandlungsverfahren
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
DE59600683D1 (de) 1996-11-27 1998-11-19 Pfleger R Chem Fab Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
JP2002503224A (ja) 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
CA2304112A1 (en) * 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
JP2001520195A (ja) 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
JP2002511414A (ja) * 1998-04-09 2002-04-16 ファルマシア・アンド・アップジョン・カンパニー 神経疾患のための新しい治療
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
PT1075264E (pt) * 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
BR9912508A (pt) 1998-06-29 2001-05-02 Pharmaceuticals Applic Associa Métodos e composições transdérmicas para alìvio da dor
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ES2247572T3 (es) 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
NZ520975A (en) 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
JP2003503450A (ja) 2003-01-28
US20060135520A1 (en) 2006-06-22
ATE320257T1 (de) 2006-04-15
NZ515885A (en) 2004-08-27
US20040147614A1 (en) 2004-07-29
JP2006143749A (ja) 2006-06-08
AU2004202096A1 (en) 2004-06-10
US20030040464A1 (en) 2003-02-27
EA200700232A1 (ru) 2007-06-29
AR035158A1 (es) 2004-05-05
US20060264436A1 (en) 2006-11-23
PT1196172E (pt) 2006-05-31
SK286864B6 (sk) 2009-06-05
KR100935277B1 (ko) 2010-01-06
HUP0201623A2 (en) 2002-09-28
EA200501496A1 (ru) 2006-06-30
DE60035232D1 (de) 2007-07-26
KR20090087134A (ko) 2009-08-14
DE60020613D1 (de) 2005-07-07
TWI245631B (en) 2005-12-21
DE60022917T2 (de) 2006-06-29
US20090247528A1 (en) 2009-10-01
NO20091159L (no) 2002-02-19
MXPA02000562A (es) 2002-07-02
US20060128705A1 (en) 2006-06-15
US7241762B2 (en) 2007-07-10
US7317011B2 (en) 2008-01-08
EA006652B1 (ru) 2006-02-24
SK286104B6 (sk) 2008-03-05
EA200200111A1 (ru) 2002-06-27
US20020128173A1 (en) 2002-09-12
MY137348A (en) 2009-01-30
US7723334B2 (en) 2010-05-25
CN1660109A (zh) 2005-08-31
EP1196172A2 (de) 2002-04-17
ES2247572T3 (es) 2006-03-01
DE60022916D1 (de) 2006-02-09
ATE305788T1 (de) 2005-10-15
WO2001001973A8 (en) 2001-05-17
PT1459751E (pt) 2005-11-30
EP1196172B1 (de) 2006-03-15
EA200801805A1 (ru) 2008-12-30
EP2087892A3 (de) 2009-09-30
JP2006321815A (ja) 2006-11-30
IL187513A0 (en) 2008-06-05
GEP20094798B (en) 2009-10-26
SK286669B6 (sk) 2009-03-05
TWI293250B (en) 2008-02-11
US20080096890A1 (en) 2008-04-24
TW200607512A (en) 2006-03-01
KR20090087135A (ko) 2009-08-14
AU5633700A (en) 2001-01-22
US6703389B2 (en) 2004-03-09
ATE292971T1 (de) 2005-04-15
WO2001001973A2 (en) 2001-01-11
DE60023043D1 (de) 2006-02-16
DE60022916T2 (de) 2006-07-06
TW200607510A (en) 2006-03-01
US20060135521A1 (en) 2006-06-22
CN1205935C (zh) 2005-06-15
CN1660111A (zh) 2005-08-31
EA005029B1 (ru) 2004-10-28
US20080103145A1 (en) 2008-05-01
US20080103147A1 (en) 2008-05-01
US7338953B2 (en) 2008-03-04
DE60022917D1 (de) 2006-02-09
DE60022692D1 (de) 2005-10-20
ES2285645T3 (es) 2007-11-16
NO20016406L (no) 2002-02-19
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
US6642235B2 (en) 2003-11-04
ATE296634T1 (de) 2005-06-15
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
US20080103146A1 (en) 2008-05-01
TWI294779B (en) 2008-03-21
ATE305307T1 (de) 2005-10-15
EA011094B1 (ru) 2008-12-30
TW200920378A (en) 2009-05-16
KR20060099544A (ko) 2006-09-19
KR100717660B1 (ko) 2007-05-15
ES2246487T3 (es) 2006-02-16
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
EA200400589A1 (ru) 2004-12-30
ATE305306T1 (de) 2005-10-15
KR20020015363A (ko) 2002-02-27
EA200801806A1 (ru) 2008-12-30
CN1660108A (zh) 2005-08-31
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
SK19382001A3 (sk) 2002-07-02
CA2643231A1 (en) 2001-01-11
NO20091158L (no) 2002-02-19
NZ533243A (en) 2005-12-23
CL2008002867A1 (es) 2009-01-09
PT1632234E (pt) 2007-07-09
EP2087892A2 (de) 2009-08-12
US20060142289A1 (en) 2006-06-29
PE20010684A1 (es) 2001-06-24
IL147246A0 (en) 2002-08-14
TW200914027A (en) 2009-04-01
CN1289090C (zh) 2006-12-13
HUP0201623A3 (en) 2004-12-28
HK1049630A1 (en) 2003-05-23
TW200607509A (en) 2006-03-01
TWI298255B (en) 2008-07-01
BR0012136A (pt) 2002-06-11
DE60022692T2 (de) 2006-06-22
HK1076723A1 (en) 2006-01-27
US6987107B2 (en) 2006-01-17
DE60020613T2 (de) 2006-03-16
DK1459749T3 (da) 2006-01-09
US6610690B2 (en) 2003-08-26
DK1459750T3 (da) 2005-08-15
KR20050053799A (ko) 2005-06-08
IL187512A0 (en) 2008-06-05
TWI298254B (en) 2008-07-01
US20020061910A1 (en) 2002-05-23
US6465458B1 (en) 2002-10-15
CN1660110A (zh) 2005-08-31
AU2004202096B2 (en) 2005-10-20
DE60026704T2 (de) 2006-10-19
TW200407146A (en) 2004-05-16
ES2242175T3 (es) 2005-11-01
CA2375908C (en) 2006-05-30
US7276503B2 (en) 2007-10-02
CZ299847B6 (cs) 2008-12-10
CL2008002868A1 (es) 2009-01-09
PL196996B1 (pl) 2008-02-29
ES2246488T3 (es) 2006-02-16
ES2246485T3 (es) 2006-02-16
US20020107249A1 (en) 2002-08-08
EP2090312A1 (de) 2009-08-19
PT1459750E (pt) 2005-08-31
SK286667B6 (sk) 2009-03-05
ATE304358T1 (de) 2005-09-15
DE60019473T2 (de) 2006-02-23
NO20091168L (no) 2002-02-19
DK1632234T3 (da) 2007-09-17
CZ20014625A3 (cs) 2002-08-14
WO2001001973A3 (en) 2002-01-17
CL2008002866A1 (es) 2009-01-09
DE60026704D1 (de) 2006-05-11
NO20016406D0 (no) 2001-12-28
CN1379672A (zh) 2002-11-13
AU771258B2 (en) 2004-03-18
TW200607511A (en) 2006-03-01
PL352252A1 (en) 2003-08-11
ATE319453T1 (de) 2006-03-15
DE60035232T2 (de) 2008-02-14
EA008381B1 (ru) 2007-04-27
ES2258010T3 (es) 2006-08-16
KR100948757B1 (ko) 2010-03-23
KR100704319B1 (ko) 2007-04-09
ES2258251T3 (es) 2006-08-16
DE60023043T2 (de) 2006-06-14
ES2239311T3 (es) 2005-09-16
SK286668B6 (sk) 2009-03-05
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01

Similar Documents

Publication Publication Date Title
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
EP1117431A4 (de) Behandlung von acidose
ATE298569T1 (de) Virus behandlung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE267598T1 (de) Virus behandlung
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
EP1244467A4 (de) Phospholglyerat-kinase zur behandlung von krankheiten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN CO. LLC, KALAMAZOO, MICH., US

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT